Scientists discover that a single gene mutation can change entire biological communities

New research through recombinant rat proteins has found that one gene mutation in a single species can trigger great changes in whole biological communities.

Scientists from Trinity College Dublin use bacteria to replicate ecological systems in the lab and found that mutations of a single gene that change how one bacterial species interacts with others had huge structural impacts across their multi-species microbial communities. These mutants produce biofilms according to their ability and many of which cause great health problems in body. It had chain effect on other species and completely changes the structure of the communities.

"We know that predators are hugely important in influencing how ecosystems are structured, as they control the numbers and diversity of other species in the food web. It is incredible that such a small genetic change can cause these mutants to completely alter communities as much as the extinction of something as important as a predator," said Assistant Professor in Zoology at Trinity, Dr Ian Donohue.

The study shows wide scope for fine-scale genetic differences within populations to change entire ecosystems including microbial ones to lakes, forests and marine system.

"It's amazing to know that just one change in a single gene has the potential to have such a huge effect that it can change whole ecosystems," said Deirdre McClean, lead author of the study and PhD Researcher in Zoology at Trinity.

The results will be helpful to disease researchers, drug developers, ecologists and even geneticists. Besides, better understanding of the effect will be critical to develop treatments aimed at manipulating our gut microbiota specifically. Flarebio provides recombinant proteins of good quality like recombinant APP at good prices.

Scientists develop new technology to repair broken proteins

A new technology is developed to help scientists understand the work process of proteins and fix the broken proteins. Researchers used to make use of many kinds of recombinant proteins such as recombinant mouse proteins and recombinant dog proteins to conduct related research. The user-friendly technology is believed to lend a hand to finding new drugs for many diseases, including cancer.

As we know that the human body has a coordinating way of turning its proteins on and off to alter their function and activity in cells. It is phosphorylation, which is the reversible attachment of phosphate groups to proteins. They provide an enormous variety of function and are essential to all forms of life. However, we know little about the detail of this dynamic process.

Researchers have built a cell-free protein synthesis platform technology that can manufacture large quantities of these human phosphoproteins for scientific study using a special strain of E. coli bacteria. The technology can enable scientists to learn more about the function and structure of phosphoproteins and identify the one which are involved in disease. The study was published Sept. 9 by the journal Nature Communications.

Trouble in the phosphorylation process is a trait of disease like cancer, inflammation and Alzheimer's disease. The human proteome is estimated to be phosphorylated at more than 100,000 unique sites. It makes study of phosphorylated proteins and their role in disease is a tough task.

The new technology just developed begins to make the job a tractable problem. It can make these special proteins at unprecedented yields, with a freedom of design that is not possible in living organisms. The consequence of this innovative strategy is enormous in the long run.

Michael C. Jewett is a biochemical engineer who led the Northwestern team. He uses cell-free systems to create new therapies, chemicals and novel materials to impact public health and the environment. Jewett and his colleagues combined state-of-the-art genome engineering tools and engineered biological "parts" into a "plug-and-play" protein expression platform that is cell-free. Cell-free systems activate complex biological systems without using living intact cells. Crude cell lysates, or extracts, are employed instead.

To be specific, the researchers prepared cell lysates of genomically recoded bacteria that incorporate amino acids not found in nature. This allowed them to harness the cell's engineered machinery and turn it into a factory, capable of on-demand biomanufacturing new classes of proteins.

The manufacturing technology will help scientists to unlock the phosphorylation 'code' that exists in the human proteome. The study was published on Sept. 9 by the journal Nature Communications. Flarebio provides you with superior recombinant proteins like recombinant Adam19 at good prices.

Fluorescent protein helps to conduct the study of arrhythmia

Stem cell-derived cell models play an increasingly important role in cardiac dysfunction studies. Researchers at Technical University of Munich (TUM) have successfully produced cells which are helpful to the studies of cardiac cell characteristics. Using glowing molecular sensors and recombinant human proteins will not only make the electrical activity of the cells visible, but also makes it possible to quickly identify the type of cell for the first time.

In the past decade, it has been possible to produce so-called induced pluripotent stem cells in the laboratory. These stem cells are derived from white blood cells - for example - they can be infinitely replicated in the laboratory and turn into all possible cell types. For example, heart cells generated in this way can be used to investigate arrhythmia. The can be used in animal experiments in the application and can't easily remove samples of tissue from the patient's heart. However, the cultured heart cells provide an opportunity to study such diseases in an approach of "microcosm".

"Our study addresses several problems using this type of cell model", said Dr. Daniel Sinnecker of Heart disease at Technical University of Munich. Heart cells produced in laboratory still have the problem of how to best measure the electrical activity. In the past, microelectrode is the most commonly to be used to directly determine the electrical signal of cells. However, this process is quite complicated and can only be used on a small number of cells.

The article published by Daniel Sinnecker and his team in the journal the heart of Europe offers a possible solution for the problem. Unlike making cell attaching microelectrode and other methods, the scientists used a biosensor. These are derived from fluorescence, i.e. Luminous - deep-sea jellyfish protein. Introduce DNA containing these sensor proteins "construction plans" into heart cells and then the protein of the sensor is produced. If giving labeled heart cells with a specific wavelength of light stimulation, they will produce light at different wavelengths. The returned exact color of the light depends on the voltage difference between the inside and outside of cells. Therefore, scientists can use a special camera to measure and record action potentials of single cells.

A special feature of this new approach is that the inserted DNA can be coupled with specific recognition sequences which are so-called promoters. These sensors ensured that the presence of protein production is only in a specific type of heart muscle cells. So it can capture the electrical signals from cells of atrium, ventricles and atrionector. Flarebio offers recombinant proteins of good quality such as recombinant Ext2 at competitive prices.

A small molecule that can help to reduce AML relapse

Researchers have made a small molecule that could deliver a one-two punch to proteins that resist chemotherapy in patients with AML. The researchers are from Rice University, Baylor College of Medicine and the University of Texas MD Anderson Cancer Center. It may be the key to helping patients who are fighting acute myeloid leukemia (AML) avoid a relapse. There are many kinds of recombinant proteins such as recombinant horse proteins used in the research.

The work led by Rice chemist Zachary Ball, Baylor pediatrician Michele Redell and MD Anderson oncologist David Tweardy appears this week in the journal Angewandte Chemie.

The protein STAT3, interferes with chemotherapy by halting the death of cancerous cells and allowing them to proliferate. The molecule locates and attacks a previously unknown binding site on STAT3, thus disrupting its disease-promoting effects.

The STAT3 protein stands for "signal transducer and activator of transcription 3". It is a suspected factor in the relapse of nearly 40 percent of children with AML. The new proximity-driven rhodium(II) catalyst known as MM-206 finds and modifies an inhibitor-binding site on the protein's coiled coil -- literally protein coils coiled around each other -- and delivers the inhibitor, naphthalene sulfonamide, to the modified site.

"We know that increased activity of STAT3 in AML and other cancers helps the cancer cells survive chemotherapy, so any new strategy we can develop to stop that process could mean real benefit for our patients," said Redell, who is also part of the leukemia and lymphoma teams at Texas Children's Hospital.

"Our main advance, from a medicinal perspective, is that this compound also works in a mouse model," Ball said. "All the other compounds worked in cells, but in mice, they weren't potent enough or stable enough."

Follow-up studies should lead to improved versions of the complex. The new discovery is of great importance showing the way to future anti-cancer approaches. Flarebio provides you with good-quality recombinant proteins such as recombinant Cdh9 at good prices.

Human body will pay more for anti-infection

Evidence from the study of a research team led by Tobias Lenz and Shamil Sunyaev conducted researcher using recombinant mouse proteins and found that the variations of deleterious gene may be the cost of our genetic diversity pays in other ways which are advantageous to us. They analyzed a group of immune system proteins to help to detect foreign molecules. These genes of these proteins contain many variation points. This diversity ensures our immune system to recognize a wide range of pathogens.

The selective special form retains this change of immune proteins within a group: scientists describe it as balancing selection. The results it produces is that when a gene of several alternative variants conferred a survival advantage, it will not be selected to eliminate.

Scientists suspect that balancing selection can sometimes lead to protection against harmful gene variants. They used the example of immune system genes to conduct computer simulation of different types of choices. In these tests, they found that balancing selection not only increases the diversity of immune proteins, but also affects the adjacent DNA fragments. At the same time, reducing the total number of variable sites increases the frequency of these variants in the population - even if they are harmful.

They then compared simulation results and the genetic analysis data of 6,500 people. The analysis confirmed their suspicions. Harmful genes can escape natural selection. "I did not expect that higher pathogen resistance may lead to some accumulation of deleterious mutations, but this mutation in the crowd sustained level surprised me. It will be interesting that the number of human genetic diseases can be traced back to the pathogen we are exposed to in the development process, "Tobias said.

Next, the researchers want to check out whether the balancing selection of other sites in the genome is associated with the frequent occurance of harmful genes in the populations. Flarebio offers recombinant proteins of good quality such as recombinant Cdh10 at competitive prices.

Protein makes sense in a cell

More than a decade ago scientists found the sequencing of the human genome, and it was undoubtedly considered one of the greatest discoveries in biology. However, it was only the beginning of our in-depth understanding of how cells work. Genes are just blueprints and it is the proteins, genes' products that do much of the work in a cell. With the use of recombinant proteins like recombinant mouse proteins and recombinant horse proteins, a multinational team of scientists have sifted through cells of vastly different organisms, from amoebae to worms to mice to humans, to reveal how proteins fit together to build different cells and bodies.

The wonderful finding is a result of a collaboration between seven research groups from three countries, led by Professor Andrew Emili from the University of Toronto's Donnelly Centre and Professor Edward Marcotte from the University of Texas at Austin. The study uncovered tens of thousands of new protein interactions, accounting for about a quarter of all estimated protein contacts in a cell.

If one of these interactions is lost it can lead to disease, and the map can help scientists spot individual proteins that could be at the root of complex human disorders. Through open access databases, the data will be available to researchers across the world.

Proteins work in teams by sticking to each other to carry out their jobs. Many proteins come together to form so called molecular machines that play key roles, such a building new proteins or recycling those no longer needed by literally grinding them into reusable parts. But when it comes to the vast majority of proteins, for example, there are tens of thousands of them in human cells, we still don't know what they do. There are a lot of researchers interested in recombinant proteins focused on this topic.

Then Emili and Marcotte's map helps. Using a state-of-the-art method developed by the groups, the researchers were able to fish thousands of protein machineries out of cells and count individual proteins they are made of. They then built a network that, similar to social networks, offers clues into protein function based on which other proteins they hang out with. For example, a new and unstudied protein, whose role we don't yet know, is likely to be involved in fixing damage in a cell if it sticks to cell's known "handymen" proteins.

The study gathered information on protein machineries from nine species that represent the tree of life: baker's yeast, sea anemones, amoeba, flies, sea urchins, worms, frogs, mice and humans. The map expands the number of known proteins association over tenfold, and it will trace how they evolved as time goes on.

The researchers discovered that tens of thousands of protein associations remained unchanged since the first ancestral cell appeared, one billion years ago (!), preceding all of animal life on Earth. The researchers believe that, with tens of thousands of other new protein interactions, the map promises to open many more lines of research into links between proteins and disease, which they are keen to explore in depth over the coming years.

The study comes out in Nature on September 7. Protein assemblies in humans were often identical to those in other species, thus the study will provide the ability to study the genetic basis for a wide variety of diseases and how they present in different species. Hope more secrets can be found. Flarebio offer good-quality recombinant proteins of good quality such as recombinant Cdh9 at good prices.

New mechanism of brain disease helps to develop new therapy

A new study published by Hong Kong University of Science and Technology discovered the a new mechanism which causes autism, mental retardation, schizophrenia and other mental disorders, which is helpful for the development of new therapies for these diseases in the future.

A research team led by Professor Zhang Mingjie at Life Sciences of HKUST used recombinant human proteins and found that the human brain is responsible two molecules SynGAP and PSD-95 which are the main components of proteins in "postsynaptic density area" where nerve signals are received. It can be assembled into a network structure, and this structure will form a stable "oil-droplet shape" droplets.

The study also found that defective proteins in the brain of the autism patients would change the composition of "oil-droplet shape" droplets, thereby changing synaptic signaling activity. The researchers said these findings could explain the etiology of autism and help to understand why gene mutations altering the interaction among these proteins will lead to a series of central nervous system diseases which haven't got a method of treatment, thus injecting new inspiration for the development of therapies.

It is understood that other neuropsychiatric disorders include schizophrenia, mental disorders, depression and so on, and they have the same formation mechanism. The research results have been published in the August 25 issue of the scientific journal Cell. Flarebio offers recombinant proteins such as recombinant Cdh10 at competitive prices.